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Although the impact of HLA-A, B, C and DRB1 matching in
unrelated hematopoietic stem cell transplantation (HSCT)
has been well reported, the role of HLA-DPB1 matching for
transplant related immunological events, especially chronic
GVHD (c-GVHD), graft-versus-leukemia (GVL) effect and
their relations has not beenwell elucidated. Accumulation of
large scale unrelated HSCT patient-donor pairs and retro-
spective 6 HLA locus allele data including HLA-DPB1 in Japan
Marrow Donor Program enable us to analyze the effects of
HLA-DPB1 matching.
2177 patients met the following criteria were included: HLA-
A, B, C, DRB1 and DQB1 allele matched unrelated donor,
diagnosis of ALL (N¼738), AML (N¼1040) or CML (N¼399),
non-T cell depleted bone marrow without use of ATG, and
survived more than 100 days after transplantation. 632 pa-
tients were matched for HLA-DPB1 allele, 1181 one allele
mismatched, and 364 two allele mismatched in GVH direc-
tion. Tacrolimus-based regimen was employed in 1158 pa-
tients and cyclosporine-based regimen in 1007.
Myeloablative regimen was conditioned in 1956 patients
and non-myeloablative regimen in 221. Multivariable
competing risk regression analyses were conducted to
evaluate the impact of acute GVHD, chronic GVHD and leu-
kemia relapse after transplantation. Confounders considered
were combinations of patient age (linear), donor age (linear),
risk of leukemia relapse (low and high), GVHD prophylaxis,
preconditioning, sex matching and transplanted year. C-
GVHD was treated as time-dependent covariates.
Hazard risk (HR) of one allele and two alleles mismatch at
HLA-DPB1 locus was 0.70 (95% CI 0.58-0.84) and 0.54 (0.41-
0.71) respectively compared with DPB1match (p<0.001). HR
of limited type c-GVHD (n¼350) and extensive type c-GVHD
(n¼563) were 0.55 (0.42-0.74) and 0.45 (0.36-0.58) respec-
tively (p<0.001) compared with no c-GVHD (n¼1264).
Interaction between these two factors was not signiﬁcant
(HR¼1.25, p¼0.278). HLA-DPB1 mismatch had no impact for
c-GVHD (one allele mismatch HR of 0.98 (0.85-1.14) p¼0.84
and two allele mismatch 1.03 (0.85-1.25) p¼0.73, compared
with HLA-DPB1 match. Therefore, HLA-DPB1 matching and
c-GVHD were an independent factor to induce GVL effect.Although HLA-DPB1 mismatch showed signiﬁcant risk factor
of a-GVHD, a-GVHD showed no signiﬁcant HR for leukemia
relapse (HR of grade 1 a-GVHD (n¼640) 1.11 p¼0.32, grade 2
(n¼596) 0.91 p¼0.45, and grade 3-4 (n¼266) 0.78 p¼0.14
compared with grade 0 (n¼762).
Retrospective analysis of HLA-A, B, C, DRB1 and DQB1
complete match unrelated HSCT elucidated the biological
effect of HLA-DPB1 matching without information biases
at transplantation, showing that GVL effect was induced
by HLA-DPB1 mismatch which was independent of
c-GVHD.195
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Background: HLA mismatches in hematopoietic stem-cell
transplantation (HSCT) correlate with adverse outcome due
to increased alloreactivity. Identiﬁcation of permissible HLA-
mismatches might be beneﬁcial for donor selection when a
10/10 matched donor cannot be found.
Methods: We developed an algorithm based upon the
concept of indirect recognition of HLA mismatches to iden-
tify permissible mismatches. We subsequently analysed
whether in silico prediction of the numbers of peptides
derived from the recipients’ mismatched-HLAmolecules that
can be presented by donor-recipient shared HLA, designated
as Predicted Indirectly ReCognizable HLA-Epitopes
(PIRCHES), correlate with HSCT outcome.
The numbers of PIRCHES presented on HLA class-I
(PIRCHE-I) and -II (PIRCHE-II) were calculated for 909 re-
cipients of a single HLA mismatched unrelated donor (9/10)
using the high resolution HLA-A, -B, -C, -DRB1 and -DQB1
typings. Recipients were subsequently divided into tertiles
according to their PIRCHE score (PIRCHE-I low: 0-1, mid: 2-
4, high 5-31 and PIRCHE-II low: 0-3, mid 4-13, high 14-79).
The clinical outcome of these groups was evaluated and
compared to a reference patient group transplanted with
completely HLA-A, -B, -C, -DRB1 and -DQB1 matched do-
nors (10/10, n¼1847).
Results: Patients in the low PIRCHE tertiles had a signiﬁ-
cantly lower risk for overall mortality, DFS, TRM, and acute
and chronic GvHD, when compared to patients in the mid
and high tertiles. Moreover, these risk in the low PIRCHE
tertiles were similar to those in 10/10 HLA-matched
transplantations.
Conclusions: In this study, we demonstrate that PIRCHES
correlate with clinical alloreactivity. In particular, patients
presenting low PIRCHE-I have similar clinical outcomes as
patients transplanted with a 10/10 HLA-matched donor. Our
data thus suggest that indirect recognition of mismatched
HLA by T cells is an important mechanism in clinical allor-
eactivity after HLA-mismatched HSCT. Determining the
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allow reducing complications after HLA-mismatched HSCT
by avoiding donors that can recognize higher numbers of
PIRCHE. The present observations indicate that selection of
HLA-mismatched donors with low numbers of PIRCHES may
lead to 5-year survival probabilities similar to 10/10 matched
unrelated donors. These observations require, however,
conﬁrmation in other cohorts. Moreover, the PIRCHES
concept may also be valuable in other HSCT settings, such as
CB transplantation and HSCTwith a 10/10matched unrelated
donor that is mismatched for HLA-DPB1.Figure 1. Kaplan Meier Curves for DFS and OS196
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Background: Umbilical cord blood (UCB) is increasingly used
as a source of unrelated donor hematopoietic cells. Advan-
tages of UCB include immediate graft availability, higher
likelihood of acceptable match, and reduced likelihood and
severity of graft vs. host disease (GVHD). Incorporation of
Busulfan (Bu) with Fludarabine (Flu) in a reduced intensity
conditioning (RIC) regimen has the potential advantages of
improved disease control and acceptable toxicity.
Patients: Eighteen patients (pts), median age 57 years (yrs)
(range 27-70), median weight 83 kg (range 54-127), Karnof-
sky performance status 80-100%, underwent double unit UCB
transplantation for hematologic malignancies (AML 44%; ALL
22%) between January 2012 and February 2013. Early disease
was seen in 44%, intermediate 12%, and advanced 44%.
Adverse cytogeneticswere present in 39%. CMVseropositivity
was seen in 16/18 (89%) pts. Hematopoietic cell trans-
plantation comorbidity index (HCT-CI) scores were HCT-CI
score 0, 44%; score 1-2, 44%; and score > 3, 12%.
Methods: UCB units were 4-6/6 HLA-A, -B antigen, and DRB1
allele matched to the pt, with median 4.36 x 107 total
nucleated cells(TNC)/kg (range 2.86e6.93) per transplant.
RIC regimen included Bu 0.8 mg/kg IV q6h x 8 doses, Flu 35
mg/m2 IV/day x 5, TBI 300-450cGy total, and ATG 1.5 mg/kg/
day x 3. Cyclosporine and mycophenolate mofetil were given
for GVHD prophylaxis.
Results: Median follow up of surviving pts was 12 months.
Day 180 overall survival (OS) was 72%. One yr OS and non-
relapse mortality (NRM) were 45% and 49%, respectively.
Relapse occurred in 1 pt. Cumulative incidence of myeloid
and platelet engraftment was 83% and 72%,median 20 and 47
days (d), respectively. First chimerism evaluation occurred at
median 21 d, all evaluable patients had 95% donor chime-
rism. At day 100, 79% of evaluable pts had single UCB unit
dominance. Acute GVHD grades II-IV occurred in 39% and
grades III-IV in 6% of patients. Chronic GVHD occurred in 17%
during the follow up period. CMV reactivation occurred in 9/
15 at risk pts, median 41 d post-transplant (range 18-54). A
median of 3 CMV reactivations per pt was observed. Two
died with CMV disease during ﬁrst reactivation, while 2others developed ganciclovir resistance. EBV reactivation
occurred in 5/17 pts, 1 pt developed Post Transplant Lym-
phoproliferative Disorder (PTLD) unresponsive to therapy.
One death was due to disseminated mucor.
Discussion: Flu/Bu based RIC regimen for double unit UCB
transplantation is associated with rapid donor chimerism
and possibly reduced disease relapse. Acute GVHD incidence
was low. Failure to achieve neutrophil and platelet engraft-
ment and high incidence of viral reactivation led to signiﬁ-
cant morbidity and high 1 yr NRM. Deﬁnitive conclusions
based on the data are limited by small patient numbers and
short follow up. Further strategies are needed to improve
immune function after RIC double unit UCB transplant.197
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